XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 123 filers reported holding XENON PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,752,369 | -22.4% | 958,793 | -12.5% | 0.70% | -9.0% |
| Q2 2023 | $42,196,000 | +2.6% | 1,096,000 | -4.6% | 0.76% | -5.2% |
| Q1 2023 | $41,126,289 | -9.2% | 1,149,100 | 0.0% | 0.81% | -6.9% |
| Q4 2022 | $45,309,013 | +10.4% | 1,149,100 | +1.0% | 0.87% | +13.8% |
| Q3 2022 | $41,057,000 | +1.5% | 1,137,300 | -14.4% | 0.76% | +4.0% |
| Q2 2022 | $40,434,000 | +92.8% | 1,329,200 | +93.8% | 0.73% | +115.6% |
| Q1 2022 | $20,971,000 | +6.4% | 686,000 | +8.7% | 0.34% | +34.4% |
| Q4 2021 | $19,712,000 | +170.4% | 631,000 | +32.3% | 0.25% | +216.2% |
| Q3 2021 | $7,289,000 | -70.7% | 477,000 | -64.2% | 0.08% | -68.1% |
| Q2 2021 | $24,843,000 | -44.4% | 1,334,217 | -46.6% | 0.25% | -40.0% |
| Q1 2021 | $44,713,000 | +16.4% | 2,497,917 | 0.0% | 0.42% | +24.4% |
| Q4 2020 | $38,418,000 | +38.9% | 2,497,917 | 0.0% | 0.34% | -3.4% |
| Q3 2020 | $27,652,000 | -11.7% | 2,497,917 | 0.0% | 0.35% | -21.1% |
| Q2 2020 | $31,324,000 | +66.1% | 2,497,917 | +50.2% | 0.44% | +39.1% |
| Q1 2020 | $18,856,000 | +126.6% | 1,662,812 | +161.9% | 0.32% | +166.4% |
| Q4 2019 | $8,322,000 | +45.5% | 634,812 | 0.0% | 0.12% | +9.2% |
| Q3 2019 | $5,720,000 | -8.6% | 634,812 | 0.0% | 0.11% | +12.4% |
| Q2 2019 | $6,259,000 | -3.0% | 634,812 | 0.0% | 0.10% | -3.0% |
| Q1 2019 | $6,450,000 | +61.0% | 634,812 | 0.0% | 0.10% | +35.1% |
| Q4 2018 | $4,006,000 | -52.2% | 634,812 | 0.0% | 0.07% | -26.7% |
| Q3 2018 | $8,380,000 | +43.5% | 634,812 | 0.0% | 0.10% | +44.3% |
| Q2 2018 | $5,840,000 | +87.7% | 634,812 | 0.0% | 0.07% | +79.5% |
| Q1 2018 | $3,111,000 | +73.5% | 634,812 | 0.0% | 0.04% | +69.6% |
| Q4 2017 | $1,793,000 | -4.3% | 634,812 | 0.0% | 0.02% | +27.8% |
| Q3 2017 | $1,873,000 | -6.4% | 634,812 | 0.0% | 0.02% | -14.3% |
| Q2 2017 | $2,000,000 | -21.2% | 634,812 | 0.0% | 0.02% | -27.6% |
| Q1 2017 | $2,539,000 | -67.0% | 634,812 | -36.5% | 0.03% | -70.4% |
| Q4 2016 | $7,700,000 | -4.9% | 1,000,000 | 0.0% | 0.10% | +6.5% |
| Q3 2016 | $8,100,000 | – | 1,000,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 1,594,932 | $57,577,000 | 9.26% |
| GREAT POINT PARTNERS LLC | 850,000 | $30,685,000 | 7.39% |
| ACUTA CAPITAL PARTNERS, LLC | 272,500 | $9,837,000 | 4.24% |
| DAFNA Capital Management LLC | 375,223 | $13,546,000 | 3.64% |
| Redmile Group, LLC | 2,370,614 | $85,579,000 | 3.32% |
| Avoro Capital Advisors LLC | 4,900,000 | $176,890,000 | 3.27% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,992 | $8,880,000 | 3.00% |
| Nan Fung Group Holdings Ltd | 114,380 | $4,129,000 | 2.64% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4,504,020 | $162,595,000 | 2.46% |
| Parkman Healthcare Partners LLC | 222,597 | $8,036,000 | 2.28% |